论文部分内容阅读
目的:观察吉西他滨联合高强度聚焦超声(HIFU)治疗晚期胰腺癌的近期疗效和安全性。方法:选择晚期胰腺癌50例,分为观察组23例和对照组27例。对照组采用静脉滴注吉西他滨治疗;观察组在对照组基础上增加HIFU治疗,比较两组近期疗效和不良反应等。结果:观察组完全缓解(CR)17.4%、部分缓解(PR)30.4%,稳定(SD)30.4%,进展(PD)21.7%;对照组CR 3.7%,PR18.5%,SD 37.0%,PD 40.7%。观察组CR率、PR率显著高于对照组(P<0.05)。观察组临床受益反应(CBR)56.5%,对照组25.9%;两组比较,差异显著(P<0.05)。治疗后,观察组疼痛强度评分非常显著低于对照组(P<0.01)。观察组无脏器穿孔、大出血、腹膜炎等并发症发生。结论:吉西他滨联合HIFU治疗晚期胰腺癌疗效较好,且安全。
Objective: To observe the short-term efficacy and safety of gemcitabine combined with high intensity focused ultrasound (HIFU) in the treatment of advanced pancreatic cancer. Methods: 50 cases of advanced pancreatic cancer were selected and divided into observation group (23 cases) and control group (27 cases). The control group was treated with intravenous gemcitabine. The observation group was treated with HIFU on the basis of the control group, and the short-term curative effect and side effects were compared between the two groups. Results: The CR of the observation group was 17.4%, the PR was 30.4%, the SD was 30.4% and the progression was 21.7%. The CR of the control group was 3.7%, PR 18.5%, SD 37.0%, PD 40.7%. The CR rate and PR rate in the observation group were significantly higher than those in the control group (P <0.05). The clinical benefit response (CBR) in observation group was 56.5%, while that in control group was 25.9%. There was significant difference between the two groups (P <0.05). After treatment, pain scores in the observation group were significantly lower than those in the control group (P <0.01). Observation group of non-organ perforation, bleeding, peritonitis and other complications occurred. Conclusion: Gemcitabine combined with HIFU is effective and safe in the treatment of advanced pancreatic cancer.